Multi-active biologics in support of health
Multi-active biologics can include proteins and signaling molecules released by cells that benefit immune system development, modulation, and health. With age, everyone experiences a reduction in these valuable, secreted materials. Our technology captures these powerful factors in an investigational therapy called IMM01-STEM.
IMM01-STEM Formulation
Immunis developed a novel method to grow human cells for clinical use and direct them to become highly pure populations of defined cells. IMM01-STEM is all-natural, all-human, and represents a perfectly balanced set of cell modulators at a physiologically relevant concentration. IMM01-STEM has the potential to reintroduce these beneficial factors into the body, thus transforming our health as we age.
Pre-Clinical Safety and Efficacy Studies
Third-party preclinical safety studies confirmed the product to be safe and well tolerated.
Preclinical data supports that IMMUNA enhances metabolism and muscle regeneration. IMMUNA has also been shown to benefit vascular function, tissue inflammation, immune cell function, and exosome/extracellular vesicle composition in several age and immune-associated disease indications.
Pre-clinical studies of our investigational secretome product show a decrease in arterial stiffness with age.
Publications
Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secrotome product derived from partially differentiated human pluripotent stem cells
Dennis K Fix, Ziad S Mahmassani, Jonathan J Petrocelli, Naomi M M P de Hart, Patrick J Ferrara, Jessie S Painter, Gabriel Nistor, Thomas E Lane, Hans S Keirstead, Micah J Drummond